- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06068010
UVA Protection Factors of SPF 50 and 50+ Face Sunscreens
The goal of this observational study is to use the International Organization for Standardization (ISO) 24442:2011 in vivo method for assessment of the Ultraviolet A Protection Factor (UVAPF) of topical sunscreen products in healthy adults. The main question it aims to answer is to determine the degree of UVA-protection against UVA radiation.
An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure.
Study Overview
Status
Conditions
Detailed Description
The objective of the study conducted in accordance with the Declaration of Helsinki and national regulations regarding human studies is to evaluate the UVA protection factor of the investigational products against UVA, according to the ISO 24442:2011 methodology comparatively to a standard product (Standard S2) in healthy adult subjects.
Standard reference S2 sunscreen formula is used in a study if any test sample has an expected UVAPF of 12 or above. The mean UVAPF for the reference sample S2 is 12,7. The test result of the reference S2 UVAPF must be between 10,7 and 14,7 or the test is invalid and shall be repeated. The reference S2 may be used to validate any product test.
In order to determine the number of subjects, the 95 % confidence interval (CI) shall be taken into account. The 95 % confidence interval should lie within ±17 % of the mean UVAPF, and a minimum of 10 subjects is required.
Study Type
Enrollment (Actual)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Fitzpatrick skin phototype: II, III or IV
- colorimetric Individual Typology Angle (ITA°): 20° to 41°
- intact skin on test site
Exclusion Criteria:
- pregnant or lactating women
- subjects using medication with photo-sensitizing potential
- subjects receiving chemotherapy or radiotherapy
- subjects who have had UV exposure on the back area in the four weeks prior to UVAPF testing
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the protection factor of the investigational product against UVA
Time Frame: from baseline to 24 hours
|
The UVAPF test method uses persistent pigment darkening (PPD) responses of the skin as the end point for evaluating transmitted UVA radiation. The test is restricted to the area of the back of selected human subjects. An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure. To determine the UVAPF, incremental series of UVA exposures are delivered to five or six small sub-sites on the skin to induce darkening responses. These responses are visually assessed for pigment darkness 2 h to 24 h after UVA exposure, by the judgement of a trained evaluator. |
from baseline to 24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Caroline Le Floc'h, Cosmetique Active International
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- LRP20005-face sunscreens
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ultraviolet-Induced Change in Normal Skin
-
L'OrealRecruitingSunscreen Sensitivity | Ultraviolet-Induced Change in Normal SkinRomania
-
Weill Medical College of Cornell UniversityYouV Labs Inc.CompletedSkin Cancer | Actinic Keratoses | Behavior, Health | Ultraviolet-Induced Change in Normal Skin | Behavior, Risk ReductionUnited States
-
The University of Hong KongCompletedGynecologic Cancer | Chemotherapy-Induced ChangeHong Kong
-
University of ArizonaCompletedAlopecia | Hair Loss | Chemotherapy-Induced Change | Alopecia DrugsUnited States
-
Evelo Biosciences, Inc.CompletedKLH and Imiquimod Induced Skin Inflammation in Healthy VolunteersNetherlands
-
Istituto Ortopedico GaleazziCompletedIL-6 Concentration in the Synovial Fluid of Obese Patients is 100% Higher Than the IL-6 Concentration of the Synovial Fluid in Normal Weight PatientsItaly
-
Gary MorrowNational Cancer Institute (NCI)CompletedPain | Breast Carcinoma | Stage 0 Breast Cancer | Radiation-Induced DermatitisUnited States
-
Hospital Universitario Reina Sofia de CordobaCompletedDERMATITIS INDUCED BY RADIOTHERAPY IN PATIENTS WHITH BREAST CANCERSpain
-
Sohag UniversityRecruitingInvestigate the Change in the Weight-bearing-line (WBL) Ratio of the Ankle Joint and Ankle Joint Line Orientation After HTOEgypt
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingLiposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer PatientsChina